DocuSign (DOCU) is trading lower as the market reacts to renewed sell-side caution following recent earnings, with the latest catalyst being additional price-target reductions that frame the stock’s near-term upside as more limited amid growth and outlook questions. UBS cut its price target to $54 (from $75) while maintaining a Neutral rating, highlighting concerns around the growth outlook and helping pressure sentiment in the session.

DocuSign recently reported fiscal Q4 and full-year fiscal 2026 results and expanded its share repurchase authorization, but the debate on Wall Street remains centered on whether billings and durable growth can re-accelerate meaningfully. The stock’s move suggests investors are prioritizing forward growth visibility and valuation rather than buyback headlines alone.

Traders will be focused on incremental changes to consensus revenue and billings expectations, any further analyst rating or target changes, and management commentary on demand trends and monetization of AI-driven agreement management features. Any signs of stabilization in growth expectations—or additional reductions—could drive the next leg of price action.